October 5, 2021 – T-CURE BIOSCIENCE, INC. AND ATLAS ANTIBODIES AB ENTER A COLLABORATION AGREEMENT FOR THE DEVELOPMENT, MANUFACTURE, AND SUPPLY OF CT83 (KK-LC-1) MONOCLONAL ANTIBODIES

LOS ANGELES, CA, USA October 5, 2021 T-Cure Bioscience, [...]

By |2021-10-05T15:27:00+00:00October 5th, 2021|Uncategorized|Comments Off on October 5, 2021 – T-CURE BIOSCIENCE, INC. AND ATLAS ANTIBODIES AB ENTER A COLLABORATION AGREEMENT FOR THE DEVELOPMENT, MANUFACTURE, AND SUPPLY OF CT83 (KK-LC-1) MONOCLONAL ANTIBODIES

April 16, 2021 – T-Cure Bioscience, Inc., a privately held company focused on developing T cell receptor (TCR) therapy products for the treatment of solid tumors, today announced that management will present virtually at the following upcoming webinar and healthcare conference:

Sherman Oaks, CA – April 16, 2021 - T-Cure [...]

By |2021-04-18T03:35:51+00:00April 18th, 2021|Uncategorized|Comments Off on April 16, 2021 – T-Cure Bioscience, Inc., a privately held company focused on developing T cell receptor (TCR) therapy products for the treatment of solid tumors, today announced that management will present virtually at the following upcoming webinar and healthcare conference:

August 04, 2020 – T-Cure Bioscience Announces Expansion of Collaboration With the National Institutes of Health for T Cell Receptor (TCR) Therapy Targeting HERV-E for the Treatment of Kidney Cancer

Sherman Oaks, CA – August 04, 2020 – (BUSINESS [...]

By |2020-12-16T18:32:57+00:00December 16th, 2020|Uncategorized|Comments Off on August 04, 2020 – T-Cure Bioscience Announces Expansion of Collaboration With the National Institutes of Health for T Cell Receptor (TCR) Therapy Targeting HERV-E for the Treatment of Kidney Cancer
Go to Top